# Lilly France S.A.S., Fegersheim, France – FDA Inspections

Source: https://www.keypedia.com/companies/lilly-france-sas/27fa7368-5fb0-48b1-b161-5729c7bfa061

> Inspection records and compliance data for Lilly France S.A.S. in Fegersheim. 9 FDA inspections on record, 3 Form 483s, last inspected September 29, 2023.

---

## Details

- Name: Lilly France S.A.S.
- FEI Number: 3002807475
- Address Line 1: Zone Dactivite Centre De Production, 2 Rue Du Colonel Lilly
- City: Fegersheim
- Country Name: France
- Address: Zone Dactivite Centre De Production, 2 Rue Du Colonel Lilly, Fegersheim, France
- Country: France

## Related Documents

- FDA Inspection 1299456 - Lilly France S.A.S. - 2023-09-29 — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 29, 2023
- [483 - Lilly France S.A.S. - 2022-09-29](https://www.keypedia.com/records/483/lilly-france-sas/041c69f4-4312-492a-881f-670b2cd26c17) — source: FDA, date: September 29, 2022
- FDA Inspection 1180181 - Lilly France S.A.S. - 2021-01-15 — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 15, 2021
- FDA Inspection 1117961 - Lilly France S.A.S. - 2020-01-16 — classification: No Action Indicated (NAI), source: FDA, date: January 16, 2020
- FDA Inspection 1117961 - Lilly France S.A.S. - 2020-01-16 — classification: No Action Indicated (NAI), source: FDA, date: January 16, 2020
- [FDA Inspection 1081382 - Lilly France S.A.S. - 2019-02-19](https://www.keypedia.com/records/fda_inspections/lilly-france-sas/107930e4-af02-49fc-acbe-092ab003f224) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 19, 2019
- [FDA Inspection 1063854 - Lilly France S.A.S. - 2018-08-28](https://www.keypedia.com/records/fda_inspections/lilly-france-sas/f327e9ea-160b-4d12-8602-054ba10008d1) — source: FDA, date: August 28, 2018
- [FDA Inspection 1020863 - Lilly France S.A.S. - 2017-04-04](https://www.keypedia.com/records/fda_inspections/lilly-france-sas/e5ccc457-4508-4a84-a212-24a4fa072cb5) — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 4, 2017
- FDA Inspection 973033 - Lilly France S.A.S. - 2016-05-03 — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 3, 2016
- FDA Inspection 895455 - Lilly France S.A.S. - 2014-09-16 — classification: No Action Indicated (NAI), source: FDA, date: September 16, 2014
- FDA Inspection 808035 - Lilly France S.A.S. - 2012-09-28 — classification: No Action Indicated (NAI), source: FDA, date: September 28, 2012

## Related Companies

- [Applied Laboratories, Inc.](https://www.keypedia.com/companies/applied-laboratories-inc/f69dbcd4-a7e9-4a06-a09d-f7c9926508de)
- [Laboratorios Leon Farma SAU](https://www.keypedia.com/companies/laboratorios-leon-farma-sau/df4a3a90-1b64-426d-bd4c-c7afb792c283)
- [AstraZeneca AB](https://www.keypedia.com/companies/astrazeneca-ab/b85a1aa5-9a0c-4c1e-996d-70b40b2507de)
- [MannKind Corporation](https://www.keypedia.com/companies/mannkind-corporation/b311f335-89a1-47a3-a7dc-24d2943cf1d4)
- [Allergan Pharmaceuticals Ireland](https://www.keypedia.com/companies/allergan-pharmaceuticals-ireland/b65756b6-b7d5-438c-a312-93abdd3b372d)
- [Ingenus Pharmaceuticals NJ, LLC.](https://www.keypedia.com/companies/ingenus-pharmaceuticals-nj-llc/542b7622-3ecf-48db-9fc6-0edf6cc42665)
- [Holopack Verpackungstechnik GmbH](https://www.keypedia.com/companies/holopack-verpackungstechnik-gmbh/3e96b02f-23a1-4178-bf40-2e389739e0b0)
- [Rubicon Research Private Limited](https://www.keypedia.com/companies/rubicon-research-private-limited/07d24fe7-deaa-4c5a-9fd3-9562d3cefd6f)
- [BWXT Medical Ltd.](https://www.keypedia.com/companies/bwxt-medical-ltd/daca3574-a5c6-4ea6-9c97-48d79c797a5d)
- [Janssen Pharmaceutica, N.V.](https://www.keypedia.com/companies/janssen-pharmaceutica-nv/7ed39763-06a4-46b7-a9a1-76399c53844c)

## Related Officers

- [Investigator](https://www.keypedia.com/people/marcellinus-d-dordunoo/a0e35c24-0cf5-4b11-95ba-1693fa3ecb3a)
- [investigator](https://www.keypedia.com/people/wendy-guat-hoon-tan/c7353462-1299-46ae-a4b0-d832d870263d)